We are live on ! Find out more
LENZ

LENZ Therapeutics
LENZ

145 hedge funds and large institutions have $303M invested in LENZ Therapeutics in 2026 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 56 increasing their positions, 28 reducing their positions, and 47 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 28

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

6.39% less ownership

Funds ownership: 112.08% → 105.69% (-6.4%)

9% less funds holding

Funds holding: 160 → 145 (-15)

23% less first-time investments, than exits

New positions opened: 36 | Existing positions closed: 47

46% less capital invested

Capital invested by funds: $562M → $303M (-$258M)

54% less call options, than puts

Call options by funds: $1.1M | Put options by funds: $2.41M

Holders
145
Holders Change
-15
Holders Change %
-9.38%
% of All Funds
1.78%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
36
Increased
56
Reduced
28
Closed
47
Calls
$1.1M
Puts
$2.41M
Net Calls
-$1.31M
Net Calls Change
+$1.22M

Top Buyers

1
Squarepoint
Squarepoint
New York
+$14.3M
2
Aberdeen Group
Aberdeen Group
United Kingdom
+$9.37M
3
Bank of America
Bank of America
North Carolina
+$6.08M
4
Morgan Stanley
Morgan Stanley
New York
+$5.84M
5
BOCH
Blue Owl Capital Holdings
New York
+$5.01M

Top Sellers

1
UBS Group
UBS Group
Switzerland
-$19.9M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$13.8M
3
IECM
Intrinsic Edge Capital Management
Illinois
-$9.12M
4
GIM
Granahan Investment Management
Massachusetts
-$6.9M
5
NAMI
Nomura Asset Management International
Pennsylvania
-$6.38M
Name Holding Trade Value Shares
Change 		Change in
Stake
TI
26
Trexquant Investment
Connecticut
$1.96M +$579K +41,225 +24%
Northern Trust
27
Northern Trust
Illinois
$1.7M +$333K +23,713 +15%
Goldman Sachs
28
Goldman Sachs
New York
$1.68M -$1.04M -74,186 -29%
Marshall Wace
29
Marshall Wace
United Kingdom
$1.47M +$1.76M +125,012 +355%
YIH
30
Y-Intercept (HK)
Hong Kong
$1.45M +$1.66M +118,100 +291%
UBS Group
31
UBS Group
Switzerland
$1.44M -$19.9M -1,414,749 -90%
VPM
32
Vanguard Portfolio Management
Pennsylvania
$1.4M +$2.15M +153,004 New
Barclays
33
Barclays
United Kingdom
$1.39M +$1.11M +78,955 +109%
VFT
34
Vanguard Fiduciary Trust
Pennsylvania
$1.37M +$2.11M +149,987 New
Charles Schwab
35
Charles Schwab
California
$1.37M -$275K -19,578 -12%
HF
36
HRT Financial
New York
$1.33M -$362K -25,777 -15%
AQR Capital Management
37
AQR Capital Management
Connecticut
$1.28M +$1.97M +140,305 New
SM
38
Scoggin Management
New York
$1.14M – – –
Jacobs Levy Equity Management
39
Jacobs Levy Equity Management
New Jersey
$1.07M -$2.16M -153,908 -57%
Susquehanna International Group
40
Susquehanna International Group
Pennsylvania
$1.01M +$598K +42,582 +63%
JF
41
Jump Financial
Illinois
$917K +$834K +59,349 +145%
WP
42
Woodline Partners
California
$915K – – –
AAA
43
Affinity Asset Advisors
New York
$915K +$1.4M +100,000 New
Royal Bank of Canada
44
Royal Bank of Canada
Ontario, Canada
$870K +$731K +52,063 +121%
KBC Group
45
KBC Group
Belgium
$827K +$1.27M +90,425 New
Rockefeller Capital Management
46
Rockefeller Capital Management
New York
$671K +$355K +25,269 +53%
VCM
47
Vivaldi Capital Management
Illinois
$586K – – –
ECM
48
ExodusPoint Capital Management
New York
$527K +$484K +34,430 +149%
AC
49
AXQ Capital
New Jersey
$499K +$488K +34,729 +175%
Bank of New York Mellon
50
Bank of New York Mellon
New York
$456K +$80.7K +5,742 +13%
1
2
3 4 5

LENZ Hedge Fund Activity: Q1 2026 in Review

145 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q1 2026, worth a combined $303M — down 46% from $562M a quarter earlier.

Sellers outnumbered buyers: 47 funds closed out of LENZ and 36 opened new positions — a net loss of 11 holders — while 28 trimmed existing stakes and 56 added.

The largest buyer was Squarepoint, adding an estimated $14.3M. The largest seller was UBS Group, cutting an estimated $19.9M.

  • 145 institutional investors held LENZ Therapeutics (LENZ) as of Q1 2026, down from 160 in Q4 2025.
  • Funds reported $303M of LENZ Therapeutics stock for Q1 2026, down 46% quarter-over-quarter.
  • 36 funds opened new LENZ Therapeutics positions in Q1 2026 and 47 closed out, a net change of -11 holders.
  • The largest LENZ Therapeutics buyer in Q1 2026 was Squarepoint, an estimated $14.3M added.
  • The largest LENZ Therapeutics seller in Q1 2026 was UBS Group, an estimated $19.9M sold.

Based on aggregated 13F filings for Q1 2026.